InvestorsHub Logo
Followers 87
Posts 6641
Boards Moderated 1
Alias Born 09/18/2009

Re: Jim Jim post# 42016

Tuesday, 03/05/2024 11:02:09 AM

Tuesday, March 05, 2024 11:02:09 AM

Post# of 42746
You brought this issue up last month, Jim

February 14, 2024

Isn't HGEN bankrupt? how do HGEN share holders have any chance at success? I was under impression that assets would be sold off and HGEN stock worth nothing now.


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173844576

and I gave you my thoughts on this subject at that time

02/14/24

Hi, Jim,

Welcome to the room, and to Ihub.

If Durrant had filed a Chapter 7 bankruptcy, shareholders would have been wiped out.

But Durrant filed a reorganization bankruptcy under Chapter 11, which allows for the share structure to remain intact.

Here are a couple of articles about our previous bankruptcy, when the company was known as Kalobios, before restructuring.

https://moxreports.com/kbio-infinity-squeeze/

https://www.globenewswire.com/news-release/2017/07/27/1063782/0/en/KaloBios-To-Change-Company-Name-To-Humanigen-Inc.html

I'm looking for management to recall their loaned shares once again, and to cause yet another massive short squeeze.


https://investorshub.advfn.com/boards/replies.aspx?msg=173844576

What right does Taran have to recall the loaned shares? Did they loan any of those shares? What clinical trial relationships does Taran have with Humanigen's partners, working on bringing lenz to market for CMML, or aGvHD, or Covid, or for any of Sanofi's oncology or asthma indications? Taran's CEO Durrant could make Humanigen's CEO Durrant sign a licensing agreement, which he may have done already, if that would alleviate your concern.

But, Taran did not buy Humanigen. I think Humanigen remains on track with all of their on-going work, and the pending results of all that work are what shareholders have to look forward to accomplishing. If you think I'm missing something, maybe I am, in which case please inform me of what that is.